NEW HAVEN, Conn., Aug. 19, 2014 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced that the U.S. Patent & Trademark Office has granted
Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and
method of use claims for ACH-3102 and structurally related NS5A
inhibitor compounds. ACH-3102 is Achillion’s second generation Phase 2
NS5A inhibitor being investigated for the treatment of chronic hepatitis
C virus (HCV) infection. This patent is entitled “Substituted
aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes
and metallocenes useful for treating HCV infections,” and provides a
patent term which lasts until 2032.
“We believe that this key patent grant will provide another important
anchor for Achillion’s intellectual property portfolio. With the
issuance of this patent for our differentiated NS5A inhibitor, ACH-3102,
along with the previously granted patent for sovaprevir, our NS3/4A
protease inhibitor, we are pleased to recognize the talented Achillion
team that discovered and has advanced these compounds into Phase 2
trials evaluating their use in all-oral combination regimens for the
treatment of chronic HCV,” commented Milind Deshpande, President and
Chief Executive Officer of Achillion.
The hepatitis C virus is the most common cause of viral hepatitis,
which is an inflammation of the liver. It is currently estimated that
more than 150 million people are infected with HCV worldwide including
more than 5 million people in the United States. Three-fourths of the
HCV patient population is undiagnosed; it is a silent epidemic and a
major global health threat. Chronic hepatitis, if left untreated, can
lead to permanent liver damage that can result in the development of
liver cancer, liver failure or death.
About Achillion Pharmaceuticals
Achillion is an innovative pharmaceutical company dedicated to bringing
important new treatments to patients with infectious disease.
Achillion’s discovery, clinical development, and commercial teams have
advanced multiple novel product candidates with proven mechanisms of
action into studies and toward the market. Achillion is focused on
solutions for the most challenging problems in infectious disease
including HCV and resistant bacterial infections. For more information
on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.